BRCC3 [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= BRCC3 =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: BRCC3
  * **<color #00a2e8>Official Name</color>**: BRCA1/BRCA2-containing complex subunit 3
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=79184|79184]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P46736|P46736]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=BRCC3&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20BRCC3|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/300617|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  This gene encodes a subunit of the BRCA1-BRCA2-containing complex (BRCC), which is an E3 ubiquitin ligase. This complex plays a role in the DNA damage response, where it is responsible for the stable accumulation of BRCA1 at DNA break sites. The component encoded by this gene can specifically cleave Lys 63-linked polyubiquitin chains, and it regulates the abundance of these polyubiquitin chains in chromatin. The loss of this gene results in abnormal angiogenesis and is associated with syndromic moyamoya, a cerebrovascular angiopathy. Alternative splicing results in multiple transcript variants. A related pseudogene has been identified on chromosome 5. [provided by RefSeq, Jun 2011]. 
  * **<color #00a2e8>UniProt Summary</color>**: N/A

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|Mov34|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|nuclear ubiquitin ligase complex|
|histone H2A K63-linked deubiquitination|
|BRISC complex|
|BRCA1-A complex|
|Lys63-specific deubiquitinase activity|
|signal transduction involved in G2 DNA damage checkpoint|
|enzyme regulator activity|
|histone deubiquitination|
|G2 DNA damage checkpoint|
|response to X-ray|
|polyubiquitin modification-dependent protein binding|
|protein K63-linked deubiquitination|
|thiol-dependent ubiquitinyl hydrolase activity|
|double-strand break repair via nonhomologous end joining|
|metallopeptidase activity|
|non-recombinational repair|
|positive regulation of DNA repair|
|signal transduction involved in DNA integrity checkpoint|
|signal transduction involved in DNA damage checkpoint|
|signal transduction involved in cell cycle checkpoint|
|positive regulation of response to DNA damage stimulus|
|negative regulation of cell cycle G2/M phase transition|
|signal transduction in response to DNA damage|
|ubiquitin ligase complex|
|thiol-dependent ubiquitin-specific protease activity|
|spindle pole|
|regulation of DNA repair|
|DNA damage checkpoint|
|DNA integrity checkpoint|
|response to ionizing radiation|
|double-strand break repair|
|positive regulation of DNA metabolic process|
|cell cycle checkpoint|
|regulation of cell cycle G2/M phase transition|
|regulation of response to DNA damage stimulus|
|negative regulation of cell cycle phase transition|
|protein deubiquitination|
|protein modification by small protein removal|
|negative regulation of cell cycle process|
|regulation of DNA metabolic process|
|histone modification|
|covalent chromatin modification|
|response to radiation|
|regulation of cell cycle phase transition|
|cell division|
|DNA repair|
|negative regulation of cell cycle|
|chromatin organization|
|regulation of cellular response to stress|
|DNA metabolic process|
|regulation of cell cycle process|
|cellular response to DNA damage stimulus|
|protein modification by small protein conjugation or removal|
|chromosome organization|
|response to abiotic stimulus|
|regulation of cell cycle|
|proteolysis|
|cell cycle|
|regulation of response to stress|
|intracellular signal transduction|
|cellular response to stress|
|positive regulation of nucleobase-containing compound metabolic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.23|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-2.15|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-1.92|
|[[:results:exp198|Etoposide 0.1μM R05 exp198]]|-1.89|
|[[:results:exp444|THZ531 0.225μM R08 exp444]]|-1.83|
|[[:results:exp539|42°C R08 exp539]]|1.7|
|[[:results:exp236|GSK2606414 1μM R05 exp236]]|1.71|
|[[:results:exp485|GSK626616 14μM R08 exp485]]|1.73|
|[[:results:exp348|Cyclosporin-A 3μM R07 exp348]]|1.76|
|[[:results:exp300|VE-822 0.04μM R06 exp300]]|1.76|
|[[:results:exp19|Etoposide 1μM R00 exp19]]|1.77|
|[[:results:exp134|MS023 2μM R03 exp134]]|1.83|
|[[:results:exp135|MS023 7μM R03 exp135]]|1.89|
|[[:results:exp28|Pimelic-diphenylamide-106 5μM R00 exp28]]|1.91|
|[[:results:exp342|Calcium Ionophore 0.4μM R07 exp342]]|1.93|
|[[:results:exp220|BAY-598 4μM R05 exp220]]|1.94|
|[[:results:exp228|Demecolcine 0.03μM R05 exp228]]|1.95|
|[[:results:exp241|QNZ 0.01μM R05 exp241]]|1.98|
|[[:results:exp365|I-BRD9 4μM R07 exp365]]|2.25|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|2.28|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:h:hars|HARS]]|0.472|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/683
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/26|
|bone|0/25|
|breast|0/30|
|central nervous system|0/49|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/11|
|fibroblast|0/1|
|gastric|0/14|
|kidney|0/18|
|liver|0/19|
|lung|0/72|
|lymphocyte|0/14|
|ovary|0/25|
|pancreas|0/22|
|peripheral nervous system|0/15|
|plasma cell|0/12|
|prostate|0/1|
|skin|0/20|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/28|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 16548
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 5.37 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='BRCC3 Expression in NALM6 Cells: 5.37'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>